MedGenome launches gene test for CLLDecember 13, 2018
MedGenome has introduced the IGHV (immunoglobulin heavy chain) gene mutation testing for chronic lymphocytic leukemia (CLL) diagnosis.
Current guidelines for CLL management involves a comprehensive molecular workup that includes some genetic tests performed on the patient’s blood or bone marrow sample. The tests enable oncologists to assess the prognosis of the disease subtype and further manage the disease by personalized therapy.
Four of the important biomarker tests includes those for somatic hypermutations (SHM) of the immunoglobulin heavy chain variable region genes (IGHV) and somatic mutations of genes such as TP53, NOTCH1 and SF3B1.
Based on the SHM value, the disease is classified Mutated CLL (M-CLL) and Unmutated CLL (U-CLL).
The status of SHM has a clear influence on the median survival of CLL patients. Presence of SHM of the IGHV region is strongly predictive of a good prognosis, while a lack of SHM predicts a poorer prognosis. Patients with an unmutated IGHV gene usually have a more aggressive disease and shorter overall survival. Patients with a mutated IGHV gene usually have a less aggressive disease, with longer overall survival, said the company.